NEWSROOM
Press Releases by Agendia
News
Press Releases
Agendia Statement in Response to Recent ASCO Guidelines on Biomarker Assay Use in Adjuvant Breast Cancer Care
Agendia is disappointed with the recent update to the American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines and with the decision to move forward without key research that we feel would have a material Read More
Agendia and Partners Receive $6.8 million from European Commission to Study Targeted Therapies for Colorectal Cancer
IRVINE, CA and AMSTERDAM, THE NETHERLANDS – Agendia, Inc. and several European partners have received a $6.8 million European Commission grant to study targeted therapies for colorectal cancer (CRC). The grantees will test therapies matched Read More
Agendia’s MammaPrint and BluePrint Breast Cancer Tests to Be Highlighted at San Antonio Symposium
Satellite Symposium and Dinner Presentation Will Offer Latest Insights on Genomic Testing and Molecular Subtyping IRVINE, CA and AMSTERDAM, THE NETHERLANDS – New breast cancer research highlighting the value of Agendia’s MammaPrint® and BluePrint® genomic tests Read More
Agendia Highlights Study Showing MammaPrint/BluePrint Tests Predict Response to Current Breast Cancer Chemotherapy and Targeted Therapy Regimens
Researchers Present Data at Breast Cancer Symposium Showing MammaPrint/BluePrint Can Identify Women Who Benefit from Chemotherapy and Targeted Dual Anti-HER2 Drug Treatment Before Surgery IRVINE, CA and AMSTERDAM, THE NETHERLANDS – Agendia’s MammaPrint® and BluePrint® tests provide new Read More
Agendia Board of Directors Appoints Mark R. Straley as New CEO
IRVINE, CA and AMSTERDAM – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announced the appointment of veteran diagnostics industry leader Mark R. Straley as Chief Executive Officer. He succeeds Read More
NCCN Breast Cancer Guidelines Acknowledge MammaPrint’s Ability to Predict Prognosis
Respected Panel Cites RASTER, the Only Published Prospective Outcome Data of Its Kind, Which Demonstrates MammaPrint’s Ability to Identify Those Patients Who May Safely Forego Chemotherapy IRVINE, CA and AMSTERDAM, THE NETHERLANDS – Agendia, a Read More
Agendia Announces Recommendation of MammaPrint in Germany’s AGO Guidelines, at St. Gallen International Breast Cancer Conference
Company Also Highlights FDA Clearance of MammaPrint in FFPE IRVINE, CA and AMSTERDAM, THE NETHERLANDS – Agendia, a leading molecular diagnostics company that develops and markets genomic diagnostic products, announced at the St. Gallen International Read More
